Celyad Oncology S.A.

CLYYFOTCHealthcare● Active

$0.25

+$0.00(+0.00%)

Market Cap$11190476

P/E Ratio—

52W High$0.53

52W Low$0.15

Avg Volume127

Open$0.32

Beta1.20

Net Income Financials Revenue

Celyad Oncology S.A. (CLYYF) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

CLYYF · net income · updated Jun 9, 2026

Core profitability metrics

CLYYF · net income · margin · TTM · CAGR

Net income was $829,688 for FY2025 (fiscal year ending 2025-12-31), up 114.2% year-over-year. Net profit margin was 3952.6%. Based on available data, Celyad Oncology S.A. has been profitable since at least 2025.

FY2025 Net Income$829,688▲ +114.2% YoY

Trailing 12M (TTM)−$5.0Mtrailing 4 quarters sum

Net Profit Margin> 999%$829,688 ÷ $20,991

YoY Change+114.2%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2025

▸ FMP /income-statement · Annual · CLYYF net income history · CLYYF profit margin

Annual net income data

CLYYF · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025★ First Profit$829,688▲ +114.2%3952.6%$20,991

FY2024Loss−$5.8M▲ +31.1%-3131.2%$186,000

FY2023Loss−$8.4M▲ +79.4%-8282.4%$102,000

FY2022Loss−$40.9M▼ 54.4%—$0

FY2021Loss−$26.5M▼ 51.5%—$0

Net income vs peers (Healthcare)

CLYYF vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Celyad Oncology S.A.YOU

CLYYF

$829,688+114.2%3952.6%

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Celyad Oncology S.A. (CLYYF) reported net income of $829,688 for FY2025 (fiscal year ending 2025-12-31), up 114.2% year-over-year. The net profit margin was 3952.6% — meaning the company kept $39.53 of every dollar of revenue as profit.

Based on available data, Celyad Oncology S.A. has been profitable since at least 2025. Net income reached a peak of $829,688 in FY2025. Data available for 15 fiscal years.

Celyad Oncology S.A.'s net profit margin was 3952.6% for FY2025, based on the latest annual results.

Investors sometimes search for "Celyad Oncology S.A. net worth" — the company's market capitalization is a separate figure from CLYYF net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

CLYYF net income · 5 questions

Celyad Oncology S.A. is profitable. The company reported net income of $829,688 for FY2025, a net profit margin of 3952.6%. Net income was up 114.2% year-over-year. Based on available data, Celyad Oncology S.A. has been profitable since at least 2025.

is CLYYF profitabledoes CLYYF make a profitCLYYF profitabilityCLYYF profitable company

▸ Source: FMP /income-statement · GAAP · Celyad Oncology S.A. · Celyad Oncology S.A. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026